Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
A new variation of the fake recruiter campaign from North Korean threat actors is targeting JavaScript and Python developers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results